Steven A. Kuross

1.8k total citations
19 papers, 1.4k citations indexed

About

Steven A. Kuross is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Steven A. Kuross has authored 19 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Steven A. Kuross's work include Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Treatment and Pharmacology (3 papers). Steven A. Kuross is often cited by papers focused on Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Treatment and Pharmacology (3 papers). Steven A. Kuross collaborates with scholars based in United States, United Kingdom and Brazil. Steven A. Kuross's co-authors include Robert Dreicer, Charles L. Loprinzi, Robert E. Coleman, Allan Lipton, Lee S. Rosen, Lester Porter, Anthony Howell, John J. Seaman, Judith R. OʼFallon and James R. Jett and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Steven A. Kuross

19 papers receiving 1.3k citations

Peers

Countries citing papers authored by Steven A. Kuross

Since Specialization

Citations

This map shows the geographic impact of Steven A. Kuross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven A. Kuross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven A. Kuross more than expected).

Fields of papers citing papers by Steven A. Kuross

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven A. Kuross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven A. Kuross. The network helps show where Steven A. Kuross may publish in the future.

Co-authorship network of co-authors of Steven A. Kuross

This figure shows the co-authorship network connecting the top 25 collaborators of Steven A. Kuross. A scholar is included among the top collaborators of Steven A. Kuross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven A. Kuross. Steven A. Kuross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Sumithra J. Mandrekar, Yingwei Qi, Shauna L. Hillman, Katie L. Allen Ziegler, Nicholas F. Reuter, Kendrith M. Rowland, Steven A. Kuross, Randolph S. Marks, Steven E. Schild, Alex A. Adjei	32
2	Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials 2009 ·Journal of Clinical Oncology ·Nathan R. Foster, (unknown), James E. Krook, J. W. Kugler, Steven A. Kuross, (unknown), Julian R. Molina, Steven E. Schild, Alex A. Adjei, (unknown)	1
3	Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial 2005 ·Investigational New Drugs ·Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer, Joel M. Reid, Mary J. Kuffel, Matthew M. Ames, Bernd W. Scheithauer, Julie E. Hammack, (unknown), Steven A. Kuross	16
4	Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium 2004 ·Cancer ·Robert Dreicer, Judith Manola, Bruce J. Roth, William A. See, Steven A. Kuross, Martin J. Edelman, Gary R. Hudes, George Wilding	134
5	Ethical Wills and Suffering in Patients with Cancer: A Pilot Study 2004 ·Journal of Palliative Medicine ·Charles E. Gessert, (unknown), Steven A. Kuross, (unknown), Irina V. Haller	8
6	Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules 2004 ·Journal of Clinical Oncology ·Alex A. Adjei, S. Nair, Nicholas F. Reuter, (unknown), Steven A. Kuross, K. M. Rowland, Preston D. Steen, Shauna L. Hillman, Steven E. Schild, (unknown)	1
7	Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules 2004 ·Journal of Clinical Oncology ·Alex A. Adjei, (unknown), Nicholas F. Reuter, Sumithra J. Mandrekar, Steven A. Kuross, K. M. Rowland, Preston D. Steen, Shauna L. Hillman, Steven E. Schild, James R. Jett	9
8	Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer 1 1This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Additional participating institutions included Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Meritcare Hospital CCOP, Fargo, ND; Sioux Community Cancer Consortium, Sioux Falls, SD; Geisinger Clinical Oncology Program, Danville, PA (Suresh Nair, M.D.); Rapid City Regional Oncology Group, Rapid City, SD (Larry P. Ebbert, M.D.), Saskatchewan Cancer Centre, Saskatoon, Saskatchewan, Canada; Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (Maria Tria Tirona, M.D.); Scottsdale CCOP, Scottsdale, AZ (Tom R. Fitch, M.D.); Carle Cancer Center CCOP, Urbana, IL (Kendrith M. Rowland, M.D.); Medcenter One Health Systems, Bismarck, ND (Ferdinand Addo, M.D.); Altru Health Systems, Grand Forks, ND (Daniel J. Walsh, M.D.); Siouxland Hematology-Oncology Associates, Sioux City, IA (John C. Michalak, M.D.); and CentreCare Clinic, St. Cloud, MN (Harold E. Windschitl, M.D.). 2002 ·International Journal of Radiation OncologyBiologyPhysics ·Steven E. Schild, Philip J. Stella, Susan M. Geyer, James A. Bonner, Randolph S. Marks, William L. McGinnis, (unknown), Steven A. Kuross, James A. Mailliard, John W. Kugler, Paul Schaefer, James R. Jett	71
9	A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer 2002 ·Annals of Oncology ·Edith A. Perez, L. Geeraerts, Vera J. Suman, Alex A. Adjei, Andre T. Baron, Alan K. Hatfield, Nita J. Maihle, J C Michalak, Steven A. Kuross, J. W. Kugler, Jacqueline M. Lafky, James N. Ingle	32
10	Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases 2001 ·Cancer ·(unknown), Lee S. Rosen, Anthony Howell, Lester Porter, Robert E. Coleman, (unknown), Robert Dreicer, Steven A. Kuross, Allan Lipton, John J. Seaman	398
11	A phase III study of radiation therapy plus carmustine with or without recombinant interferon-? in the treatment of patients with newly diagnosed high-grade glioma 2001 ·Cancer ·Jan C. Buckner, Paula J. Schomberg, William L. McGinnis, Terrence L. Cascino, Bernd W. Scheithauer, Judith R. OʼFallon, Roscoe F. Morton, Steven A. Kuross, James A. Mailliard, Alan K. Hatfield, John T. Cole, Preston D. Steen, Albert M. Bernath	107
12	Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. 2000 ·PubMed ·Patrick A. Burch, (unknown), G. Schroeder, J. W. Kugler, Daniel J. Sargent, (unknown), J A Mailliard, J C Michalak, Alan K. Hatfield, Kyle Wright, Steven A. Kuross	23
13	Paclitaxel and G-CSF in Previously Untreated Patients With Extensive Stage Small-Cell Lung Cancer 1999 ·American Journal of Clinical Oncology ·(unknown), Joseph P. Grill, Randolph S. Marks, John W. Kugler, James B. Gerstner, Steven A. Kuross, John C. Michalak, Harold E. Windschitl, (unknown), James R. Jett	48
14	Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. 1998 ·Journal of Clinical Oncology ·Jeff A. Sloan, Charles L. Loprinzi, Steven A. Kuross, Angela W. Miser, Judith R. OʼFallon, M. R. Mahoney, Iris M. Heid, Mary E. Bretscher, Nancy L. Vaught	198
15	Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. 1996 ·Journal of Clinical Oncology ·Kendrith M. Rowland, Charles L. Loprinzi, Edward G. Shaw, Andrew W. Maksymiuk, Steven A. Kuross, Sang Hoon Jung, J. W. Kugler, Loren K. Tschetter, C Ghosh, Paul Schaefer, Donald R. Owen, (unknown), Thomas A. Webb, J A Mailliard, James R. Jett	103
16	Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. 1994 ·Journal of Clinical Oncology ·Charles L. Loprinzi, Richard M. Goldberg, John Q. Su, J A Mailliard, Steven A. Kuross, Andrew W. Maksymiuk, J. W. Kugler, James R. Jett, C Ghosh, (unknown)	78
17	Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy 1994 ·Cancer ·James N. Ingle, Steven A. Kuross, James A. Mailliard, Charles L. Loprinzi, Sin‐Ho Jung, Robert A. Nelimark, James E. Krook, Harry J. Long	16
18	Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. 1994 ·Journal of Clinical Oncology ·Charles L. Loprinzi, Steven A. Kuross, Judith R. OʼFallon, Dean H. Gesme, James B. Gerstner, Raylene M. Rospond, Charles D. Cobau, Richard M. Goldberg	69
19	Wegener's granulomatosis with severe renal failure: clinical course and results of dialysis and transplantation. 1981 ·PubMed ·Steven A. Kuross, (unknown), C.M. Kjellstrand	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact